GlobalData on MSN15d
Adaptimmune nears second sarcoma approval as Phase II trial hits endpointsAdaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.
Researchers observed responses in patients with synovial sarcoma or myxoid/round cell liposarcoma treated with lete-cel.
Adding pembrolizumab to radiotherapy and surgery can improve disease-free survival in patients with certain types of sarcoma.
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Synovial Sarcoma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering A groundbreaking insight into the Synovial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback